Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Anti–PD-1 inhibitor"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract This study aimed to investigate the associations between the clinical characteristics and effectiveness of anti-PD-1 inhibitors in patients with EGFR-sensitive mutations, aiming to identify the potential subgroup of patients who might benefi
Externí odkaz:
https://doaj.org/article/fe367213807e454f8449b7d4e4b3c515
Publikováno v:
International Journal of General Medicine, Vol Volume 16, Pp 4485-4498 (2023)
Shu-hui Li, Yi-Wen Li, Ying-Jue Li, Lin-Bo Liu, Qun Zhang, Dan Lu Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, 150086, People’s Republic of ChinaCorrespondence: Dan Lu, Depa
Externí odkaz:
https://doaj.org/article/f13f5666e8af48baa7ca0791bf0e2735
Autor:
Yi-Shan Teng, Sebastian Yu
Publikováno v:
Current Oncology, Vol 30, Iss 7, Pp 6805-6819 (2023)
Over the past few decades, immune checkpoint inhibitors (ICIs) have emerged as promising therapeutic options for the treatment of various cancers. These novel treatments effectively target key mediators of immune checkpoint pathways. Currently, ICIs
Externí odkaz:
https://doaj.org/article/98594afe564a43439bfaeceba6c3a38b
Autor:
Sze Wah Samuel Chan, Rahul Shukla, Jennifer Ramsay, Elaine McWhirter, Paul Barnfield, Rosalyn A. Juergens
Publikováno v:
Current Oncology, Vol 30, Iss 5, Pp 4527-4537 (2023)
Background: Immune checkpoint inhibitors (ICI) are increasingly the mainstay of oncology treatment. Immune-related adverse events (irAEs) from ICI therapy differ from cytotoxic adverse events. Cutaneous irAEs are one of the most common irAEs and requ
Externí odkaz:
https://doaj.org/article/484ae326ad3842b8a98eb90c9cebd229
Publikováno v:
Современная онкология, Vol 24, Iss 4, Pp 426-439 (2023)
Aim. To assess the comparative clinical efficacy of Prolgolimab monotherapy versus combination therapy with BRAF/MEK inhibitors (Dabrafenib and Trametinib, Vemurafenib and Cobimetinb) in adult patients with metastatic or unresectable skin melanoma im
Externí odkaz:
https://doaj.org/article/aafcc14c962f49df898fc6b6e3b63b9a
Publikováno v:
Current Oncology, Vol 29, Iss 4, Pp 2871-2886 (2022)
Immune checkpoint inhibitors (ICIs) have emerged as novel options that are effective in treating various cancers. They are monoclonal antibodies that target cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1), and programmed cel
Externí odkaz:
https://doaj.org/article/ddab82e5184b4093abdcd73ba19d6559
Autor:
Hitomi Jo, MD, PhD, Tatsuya Yoshida, MD, PhD, Shigehiro Yagishita, MD, PhD, Mayu Ohuchi, PhD, Yuji Matsumoto, MD, PhD, Yuki Shinno, MD, PhD, Yusuke Okuma, MD, PhD, Yasushi Goto, MD, PhD, Hidehito Horinouchi, MD, PhD, Noboru Yamamoto, MD, PhD, Kazuhisa Takahashi, MD, PhD, Noriko Motoi, MD, PhD, Akinobu Hamada, PhD, Yuichiro Ohe, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 4, Pp 100474- (2023)
Introduction: Immune checkpoint inhibitors (ICIs) induce long-term, durable responses in patients with advanced NSCLC. Nevertheless, these responses are limited to a few patients, and most responders have disease progression. The purpose of this stud
Externí odkaz:
https://doaj.org/article/fbc7fcbfc26745ea85440370d0442d63
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Vincent T. Ma, Charles S. Katzman, Phillip L. Palmbos, Rajiv M. Patel, Johann E. Gudjonsson, Ajjai S. Alva
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 1, Iss , Pp 100004- (2020)
Immune-mediated cutaneous reactions are a frequent occurrence in cancer patients treated with immune checkpoint inhibitors. A small subset of these adverse events are psoriasiform reactions. To date, there is no high-level evidence supporting the mos
Externí odkaz:
https://doaj.org/article/b542242dacf0436baa4cc6c44c36c7f7